(0.15%) 5 099.25 points
(0.53%) 38 586 points
(0.41%) 17 722 points
(0.38%) $79.25
(-0.34%) $2.03
(-0.05%) $2 308.50
(-0.15%) $26.79
(0.39%) $966.40
(-0.07%) $0.932
(-0.20%) $10.97
(-0.12%) $0.797
(0.66%) $91.73
Live Chart Being Loaded With Signals
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...
Stats | |
---|---|
今日成交量 | 372 349 |
平均成交量 | 105 224 |
市值 | 380.11M |
EPS | $0 ( 2024-03-04 ) |
下一个收益日期 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.07 |
ATR14 | $0.0590 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-24 | Secor Alicia | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Secor Alicia | Sell | 105 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 44 391 | Ordinary Shares |
2024-01-24 | Geraghty James A | Sell | 46 000 | Stock Option (Right to Buy) |
2024-01-24 | Geraghty James A | Sell | 105 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-32.53 |
Last 99 transactions |
Buy: 13 341 271 | Sell: 6 351 136 |
音量 相关性
Orchard Therapeutics PLC 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Orchard Therapeutics PLC 相关性 - 货币/商品
Orchard Therapeutics PLC 财务报表
Annual | 2022 |
营收: | $6.99M |
毛利润: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2022 |
营收: | $6.99M |
毛利润: | $4.55M (65.17 %) |
EPS: | $-0.610 |
FY | 2021 |
营收: | $1.68M |
毛利润: | $1.45M (86.51 %) |
EPS: | $-1.170 |
FY | 2020 |
营收: | $2.60M |
毛利润: | $1.74M (66.97 %) |
EPS: | $-1.530 |
Financial Reports:
No articles found.
Orchard Therapeutics PLC
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。